202,541 Shares in Arbutus Biopharma Co. (NASDAQ:ABUS) Acquired by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC purchased a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 202,541 shares of the biopharmaceutical company's stock, valued at approximately $662,000. Susquehanna Fundamental Investments LLC owned 0.11% of Arbutus Biopharma at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new position in shares of Arbutus Biopharma in the 4th quarter worth $236,000. Vanguard Group Inc. raised its holdings in shares of Arbutus Biopharma by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company's stock valued at $29,367,000 after purchasing an additional 62,282 shares during the last quarter. Barclays PLC increased its holdings in shares of Arbutus Biopharma by 466.3% in the third quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company's stock valued at $1,047,000 after purchasing an additional 223,995 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Arbutus Biopharma by 900.4% in the 4th quarter. JPMorgan Chase & Co. now owns 896,258 shares of the biopharmaceutical company's stock valued at $2,931,000 after buying an additional 806,672 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Arbutus Biopharma during the 4th quarter worth approximately $301,000. 43.79% of the stock is owned by hedge funds and other institutional investors.

Arbutus Biopharma Price Performance

Shares of ABUS stock traded down $0.06 on Thursday, reaching $3.23. 338,588 shares of the company were exchanged, compared to its average volume of 993,946. The company has a 50-day moving average of $3.29 and a 200-day moving average of $3.42. The company has a market cap of $618.48 million, a price-to-earnings ratio of -7.51 and a beta of 1.50. Arbutus Biopharma Co. has a one year low of $2.71 and a one year high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $2.20 million. As a group, sell-side analysts predict that Arbutus Biopharma Co. will post -0.39 EPS for the current year.

Analyst Ratings Changes

ABUS has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. Chardan Capital reissued a "buy" rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research report on Friday, March 28th. Finally, StockNews.com raised shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, March 29th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Arbutus Biopharma has an average rating of "Moderate Buy" and an average target price of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.